151 related articles for article (PubMed ID: 8780090)
1. Rate of motor response to oral levodopa and the clinical progression of Parkinson's disease.
Contin M; Riva R; Martinelli P; Triggs EJ; Albani F; Baruzzi A
Neurology; 1996 Apr; 46(4):1055-8. PubMed ID: 8780090
[TBL] [Abstract][Full Text] [Related]
2. Locomotor response to levodopa in fluctuating Parkinson's disease.
Moore ST; MacDougall HG; Gracies JM; Ondo WG
Exp Brain Res; 2008 Feb; 184(4):469-78. PubMed ID: 17828529
[TBL] [Abstract][Full Text] [Related]
3. Levodopa peak response time reflects severity of dopamine neuron loss in Parkinson's disease.
Sohn YH; Metman LV; Bravi D; Linfante I; Aotsuka A; Mouradian MM; Chase TN
Neurology; 1994 Apr; 44(4):755-7. PubMed ID: 8164839
[TBL] [Abstract][Full Text] [Related]
4. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
5. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
Goetz CG; Stebbins GT; Blasucci LM
Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
[TBL] [Abstract][Full Text] [Related]
6. [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease.
Kumar A; Mann S; Sossi V; Ruth TJ; Stoessl AJ; Schulzer M; Lee CS
Brain; 2003 Dec; 126(Pt 12):2648-55. PubMed ID: 12937076
[TBL] [Abstract][Full Text] [Related]
7. Levodopa therapy monitoring in patients with Parkinson disease: a kinetic-dynamic approach.
Contin M; Riva R; Martinelli P; Albani F; Avoni P; Baruzzi A
Ther Drug Monit; 2001 Dec; 23(6):621-9. PubMed ID: 11802094
[TBL] [Abstract][Full Text] [Related]
8. Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function.
O'Sullivan JD; Said CM; Dillon LC; Hoffman M; Hughes AJ
Mov Disord; 1998 Nov; 13(6):900-6. PubMed ID: 9827613
[TBL] [Abstract][Full Text] [Related]
9. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
[TBL] [Abstract][Full Text] [Related]
10. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.
Fabbrini G; Juncos J; Mouradian MM; Serrati C; Chase TN
Ann Neurol; 1987 Apr; 21(4):370-6. PubMed ID: 3579222
[TBL] [Abstract][Full Text] [Related]
11. Quantification of the dopaminergic response in Parkinson's disease.
Müller T; Benz S
Parkinsonism Relat Disord; 2002 Jan; 8(3):181-6. PubMed ID: 12039429
[TBL] [Abstract][Full Text] [Related]
12. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
[TBL] [Abstract][Full Text] [Related]
13. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
[TBL] [Abstract][Full Text] [Related]
14. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
[TBL] [Abstract][Full Text] [Related]
15. Levodopa induced motor complications in Thai Parkinson's disease patients.
Kulkantrakorn K; Tiamkao S; Pongchaiyakul C; Pulkes T
J Med Assoc Thai; 2006 May; 89(5):632-7. PubMed ID: 16756048
[TBL] [Abstract][Full Text] [Related]
16. Levodopa reinstates connectivity from prefrontal to premotor cortex during externally paced movement in Parkinson's disease.
Herz DM; Siebner HR; Hulme OJ; Florin E; Christensen MS; Timmermann L
Neuroimage; 2014 Apr; 90():15-23. PubMed ID: 24269570
[TBL] [Abstract][Full Text] [Related]
17. Complexity of motor response to different doses of duodenal levodopa infusion in Parkinson disease.
Nyholm D; Johansson A; Aquilonius SM; Hellquist E; Lennernäs H; Askmark H
Clin Neuropharmacol; 2012; 35(1):6-14. PubMed ID: 22094648
[TBL] [Abstract][Full Text] [Related]
18. Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.
van Laar T
CNS Drugs; 2003; 17(7):475-89. PubMed ID: 12751918
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
20. Modulation of corticomotor excitability after maximal or sustainable-rate repetitive finger movement is impaired in Parkinson's disease and is reversed by levodopa.
Teo WP; Rodrigues JP; Mastaglia FL; Thickbroom GW
Clin Neurophysiol; 2014 Mar; 125(3):562-8. PubMed ID: 24095151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
